How MK677 liquid compares with capsules, powder and injections
MK677 liquid, capsules, tablets and powder all hold the same compound, ibutamoren, and the human trials gave it orally because it was designed as an orally active releaser of growth hormone, the pituitary hormone that drives growth and tissue repair; that role as a releaser is what separates MK-677 and HGH. The liquid is the powder dissolved in a solvent.
Outside the published trials, that solvent is described as the cause of the harsh taste of the bottled forms, and their storage is described only in such accounts, never in a stability study of a finished product.
What is MK 677, the compound behind all of these forms? Ibutamoren, a small molecule (not a peptide) selected for clinical study because it raised growth hormone after oral dosing; the human trials gave it orally once daily, and no human data stand behind an injectable form, since intravenous administration, delivery of a dose directly into the bloodstream, is documented only in beagles. What separates the bottled forms is the solvent and the handling, not the molecule.
This article compares the dosage forms of ibutamoren through what the trials, the animal studies and the accounts outside them say about each form and its storage; the physiological and adverse effects of the compound stay outside it, and so does dose except where it bears on a form.
Oral ibutamoren in the human trials
Every human trial among this article’s sources gave ibutamoren orally, once daily. In the longest, healthy older adults received the daily oral dose set out in the table, and growth hormone rose into the range of healthy young adults, as did insulin-like growth factor 1 (IGF-1), the growth factor that mediates growth hormone’s effects on tissues; the same daily dose went to obese men over a shorter course and raised IGF-1 in their serum.
The shorter trials kept to the same route. A crossover trial gave that daily dose to healthy volunteers held on a restricted diet; prepubertal children with growth hormone deficiency received the compound as ibutamoren mesylate (the salt used in the clinical programme) at the two body-weight doses the table records; and in haemodialysis patients on the same route the rise in IGF-1 was greater than on placebo.
Oral ibutamoren across the human trials
Trial population
Length
What was given
Main reported result
65 healthy adults aged 60-81
2 years
25 mg once daily, oral
Fat-free mass +1.1 kg vs -0.5 kg on placebo at 12 months; body weight +2.7 vs +0.8 kg
Serum IGF-1 up about 40 per cent; fat-free mass increased, total and visceral fat unchanged
8 healthy volunteers on 18 kcal/kg a day
7 days of dosing within a 14-day diet period
25 mg once daily, oral, crossover
Nitrogen balance +0.31 g/day vs -1.48 g/day on placebo
18 prepubertal children with growth hormone deficiency
7 to 8 days
Ibutamoren mesylate 0.2 and 0.8 mg/kg a day, oral
GH peak, IGF-1 and IGFBP-3 rose in some children at 0.8 mg/kg
22 haemodialysis patients
3 months, crossover
Oral ghrelin receptor agonist MK-0677
IGF-1 increase 65 per cent greater than placebo; no serious adverse effects attributed
The records state the route and the dose, and none says whether a daily dose was given as a tablet, a capsule or a solution: the dosage form was never the variable under study, so the trial literature settles the route and leaves the form open.
Why growth hormone is injected while ibutamoren is swallowed
Growth hormone itself has to be given subcutaneously, by injection into the tissue beneath the skin, whereas ibutamoren was designed to act after oral administration. The difference is one of oral bioavailability, the fraction of an administered dose that reaches the circulation intact, the measure that also sets SARM bioavailability after oral administration.
Ibutamoren acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor, in the hypothalamus and in the pituitary, a receptor distinct from the one for growth hormone-releasing hormone, so the two pathways are separate; through it, in the hypothalamus and then the pituitary, the growth hormone secretagogue MK 677 raises growth hormone.
[Figure 1. Ghrelin receptor pathway for oral ibutamoren. Swallowed ibutamoren acts at the growth hormone secretagogue (ghrelin) receptor in the hypothalamus and pituitary, releasing growth hormone and raising IGF-1, whereas growth hormone itself works only when injected under the skin.]
The same receptor is the target of the growth hormone-releasing peptides, short synthetic growth-hormone secretagogues that raise growth hormone after intravenous, subcutaneous, intranasal and even oral administration, and a review of the class names MK-0677 as the most interesting of their non-peptidyl mimics. That interest rested on earlier animal work, ibutamoren having been selected for clinical study after oral doses raised growth hormone in dogs, which places the oral route at the origin of the molecule rather than at the end of its development.
Ibutamoren capsules in a hair-testing study
Ibutamoren capsules enter the published record outside the trials through a hair-testing study that established reference concentrations by hair analysis, the measurement of a compound incorporated into the hair shaft. A male volunteer received a single dose, and a drug test for MK 677 on hair collected weeks later came back positive, at the concentration given in the table in picograms of compound per milligram of hair, in the segment nearest the scalp.
The second specimen came from a subject whose exposure amounted to a whole vial of capsules, and hair collected after that exposure ended tested positive at the far higher concentration the table records; the capsules also document a stated unit strength, recorded in the table, a point beyond the detection question the paper was written to answer.
Pill and liquid are described, outside the trial record, as carrying the same molecule and differing in handling rather than in the compound, which is the usual verdict on liquid SARMs vs pills as well: a pill, whether an MK-677 tablet or a capsule, holds a fixed amount in each unit, so a stated strength needs no measuring and the taste of the material stays enclosed, while MK 677 drops allow the amount drawn to be varied by volume.
In descriptions beyond the trials, MK677 in liquid form, made up as a solution from powder, is widely described as costing less per gram than finished units, and the saving comes with the taste of the solution, with a container that has to be kept sealed and dark, and with a strength that cannot be confirmed by eye.
Why does MK-677 liquid taste so bad, and how can you mask it?
The taste of MK-677 liquid is the effect raised most often among those described outside the trials, and its cause is attributed in two ways, to the solvent that carries the compound and to the raw material itself: the taste is strongly bitter and chemical, in some accounts with a note of alcohol behind it, and accounts that set out what MK 677 does taste like call it worse than other research compounds prepared as solutions, ostarine liquid and solutions of several related materials being faintly sweet or almost without flavour where the ibutamoren solution is difficult to tolerate.
In descriptions beyond the trials a minority of accounts run the other way, the powder off-white with no smell and no flavour at all and the solution tasting of almost nothing, an absence of the expected bitterness that is then read as grounds for doubting that a bottle holds what the label states, and so for seeking an analysis of the batch. Attempts to mask the bad taste of MK-677 are described too, and most are said to fail or to spread the taste rather than hide it:
The solution added to flavoured water
The solution added to fruit juice
The solution added to a sweetened carbonated drink
The solution added to a zero-calorie carbonated drink
Capsules, sometimes described as the measure that succeeded
Repeated exposure, after which a few accounts describe the taste becoming tolerable
Should MK-677 liquid have a smell?
Beyond the trial data the smell of MK-677 liquid is described inconsistently, so whether the bottled solution should have any is not agreed: some accounts have no scent at all from either the powder or the solution, set beside a markedly bitter taste, others a distinct and unpleasant odour as the usual character of the material, so that its absence is treated as odd, and an absence of both smell and taste, in a solution or in capsules, is sometimes read as a reason to doubt what the preparation contains.
Can you mix MK-677 with water or a drink to take it?
Mixing MK-677 with water or with a drink has also been described as straightforward, because the compound is readily soluble: the powder dissolves at room temperature with little difficulty in distilled and demineralised grades and in deionised water (stripped of its dissolved ions), a measured volume of an existing solution goes into a glass of juice or a carbonated drink, and a clear solution stays so when diluted that way.
Not every account outside the published studies agrees, and a minority of those accounts describe the compound as not dissolving properly in water and as needing another carrier, leaving unsettled whether water given soon after oral administration of the compound makes any difference; the contrast with other research compounds is drawn repeatedly, since the solubility of LGD-4033 and of similar compounds is nil in water, so that they require a glycol, and the question of whether a capsule can be emptied and its contents dissolved is raised, as is the reverse, a solution loaded into capsules.
How do you dissolve MK-677 powder into a liquid, and which solvent works?
Accounts outside the published studies describe ibutamoren powder as dissolving in several carriers, with no single one treated as correct: distilled and deionised water, propylene glycol (a viscous dihydric alcohol used as a pharmaceutical carrier), polyethylene glycol (PEG), a water-soluble polymer supplied in grades of average molecular weight such as the liquid PEG-400, ethanol, and dimethyl sulfoxide (DMSO), a polar solvent that dissolves many organic compounds. MK 677 solubility is described differently from one account to another, some treating water as sufficient on its own, others naming glycol and glycol-with-DMSO mixtures where a small volume has to hold a higher concentration.
Beyond the trial data, the method of preparation is volumetric rather than approximate: the raw MK 677 powder is weighed on a milligram balance, dissolved in part of the final volume and then made up to that volume, because the dissolved material occupies space of its own and a volume of solvent measured alone gives an incorrect concentration; small quantities are impossible to judge by eye, and an inexpensive balance is named as the limiting step.
Weigh the powder: weigh the material on a milligram balance and record the mass.
Record the solvent: note the solvent and keep it constant across the batch, since the accounts disagree on which performs best.
Dissolve in part of the final volume: stir the weighed material into less solvent than the final volume until no particles remain.
Make up to the final volume: bring the preparation to its final volume in a graduated vessel.
Check, label and seal: confirm that the preparation is clear, label it with the compound, solvent, strength and date, and keep it sealed away from light.
Does MK-677 solution contain ethanol, and what solvent is used?
An MK-677 solution is made, in descriptions beyond the trials, with ethanol in some cases, with water in others and with a mixture of the two and a glycol in others again, preparations built on near-pure grain ethanol standing alongside water-only ones; labels that state no composition prompt the question of whether a given bottle contains ethanol, and the taste of such solutions is attributed most often to the solvent rather than to the compound itself.
Digestive complaints blamed on the solvent
Beyond the trial data, a small set of gastrointestinal effects is described and attributed to the carrier rather than to the compound: gastric upset, rarely, in connection with a suspension, a preparation in which solid material is dispersed rather than dissolved, attributed to the solvent of that particular batch, and the same carrier singled out once as tasting unlike the other solutions of the same range and as marking the graduations on a glass dropper.
What colour should MK-677 be, and is beige or yellow normal?
In descriptions beyond the trials, the colour of MK-677 powder and of its solutions spans a described range, so beige and yellow both fall inside it, and batches differ from one another:
White and off-white
Beige or faintly yellow
A caramel shade, reached by darkening over time, described as familiar rather than alarming
Greenish-yellow through brown to colourless, described of solutions in one instance with no measured change in the purity of the raw material
Dark green or black, widely described as a reason to discard the bottle
Beyond the trial data, ibutamoreno powder is white before dissolution, and other appearances are grounds for concern: powder that changed colour in storage is taken to have broken down, or never to have been the stated compound. Reassuring and suspicious accounts alike reach one conclusion by different routes, that colour alone cannot tell a sound batch from a suspect one, because the range held to be normal overlaps the range held to be suspect, and only an analysis tells the two apart.
Are white bits or crystals floating in MK-677 liquid normal?
Among the effects described outside the trials, white bits and crystals in MK-677 liquid are common enough to take several recognised forms:
White flecks suspended in the liquid
Powder settled at the bottom of a bottle
A white layer standing over clear liquid
Crystalline growth on the outside of a container
Deposits inside a dropper
Those deposits are given two explanations outside the trial record: material that never dissolved fully settles out, and water taken up from the air forms a hydrate crystal, a solid in which water molecules sit within the crystal lattice; a solution left in the cold is also described as setting almost solid and then, as it warms, returning to a clear liquid.
Why does MK-677 liquid foam or bubble when shaken?
MK-677 liquid is generally held to foam on shaking because of its carrier rather than because of any change in the compound: the viscous solvents propylene glycol and polyethylene glycol trap air readily and release it slowly, as do preparations containing ethanol, so bubbles of this kind settle out on standing, while persistent foam points to a surface-active component in the preparation, one that cannot be identified from appearance alone.
How do you make your own MK-677 capsules?
MK-677 capsules are described, outside the trial record, as made by weighing the powder on a milligram balance and filling it into empty gelatin capsules, two-piece shells of gelatin that separate for filling, the usual alternative both to the taste of the bottled solution and to the price of finished units; the limiting step is the balance, not the shell.
In descriptions beyond the trials, several questions recur around that weighing step. The capacity of a given shell size is put in terms of displacement (the volume a weighed solid occupies in the capsule body), because a shell holds a volume and not a mass; the transfer of an existing solution into gelatin shells raises the open question of whether the transfer alters the compound; attempts to split a quantity between filled capsules and a solution are described; and one account adds a precaution, that a shell filled this way should contain the single compound and no other substance.
What laboratory stability data show for ibutamoren
The nearest thing to stability data among this article’s sources is a doping-control method paper on blood matrices, whose conditions the table below sets out. Several peptide doping agents were extensively degraded in serum and in plasma under the warmer of the conditions tested, and ibutamorenum was not among the compounds that broke down; in the freezer every analyte in the panel remained stable, within the variation and over the period the table records, in all the blood matrices examined.
Stability by temperature and blood matrix
Condition
Matrix
What the panel did
-20 °C for at least two months
All blood matrices examined
All compounds stable, variation below 15 per cent
4 and 22 °C for one week
Serum and plasma
Several peptide agents extensively degraded; ibutamorenum not among those that broke down
Non-refrigerated, whole study duration
Dried blood spots
All compounds remained detectable, so specimens can be transported and held without refrigeration
Dried blood spots, drops of whole blood dried onto a paper card, kept all of the compounds detectable for the whole study too, so such specimens can be transported and held without refrigeration. The figures describe analytical specimens rather than a product standing in a solvent, and they carry no further; heat, light and moisture each act on research compounds in a distinct way, so storing SARMs safely depends on guarding against each of the three separately.
Is MK-677 still good after being exposed to high heat?
MK-677 is described, outside the trial record, as tolerating extremes of temperature better than peptides do, and a solution carried through transit at uncontrolled temperatures as having lost little in a few accounts; high heat is the extreme raised most often, cold is raised in the same terms, and several accounts record no confidence either way without an analysis of the batch in hand. The exposures described are these:
Bottles arriving warm after transit
A bottle left in a parked car
Shipping in winter cold, which prompts the question of whether a solution has been altered
A preparation that softens or runs after warming, described, beyond the trial data, as unsettling
Is an old bottle of MK-677 still good after one or two years?
An old bottle of MK-677 has also been described as having lost little when its solution was analysed long after preparation, though only in a few accounts; in others colour and clarity are the only checks short of an analysis. Stability of that kind is judged in terms of shelf life, the period over which a preparation is held to remain within its stated strength, and the bottles in question include sealed and unopened ones recovered years later and a half-used one kept in a cupboard; the MK677 shelf life after opening is treated as a separate question, because some labels state a period measured in months.
Should MK-677 liquid go in the fridge or freezer, or a cupboard?
MK-677 liquid and capsules alike are described, in accounts outside the published studies, as keeping well enough in a cool, dry, dark cupboard, the absence of any need for refrigeration counting as an advantage over materials that must be refrigerated; refrigeration is also said to turn a solution semi-solid until it warms again, the freezer is named for storage over long periods, and the powder itself is hygroscopic, readily taking up water from the air, so sealed storage is described for it and powder that has hardened is taken to have absorbed moisture.
in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs
Chromatography is how ibutamoren batches are checked for purity, and one analytical case series sets out such a method for MK-0677 as an active pharmaceutical ingredient, the compound itself as distinct from a finished preparation. The series used reversed-phase high-performance liquid chromatography (HPLC), which separates compounds on a column before they reach the detector, to track the impurity profile, the identity and amount of the related substances present; the authors arrived at the method by screening stationary phases and varying the pH of the mobile phase, identified individual impurities by liquid chromatography-mass spectrometry (LC-MS), preparative chromatography and nuclear magnetic resonance (NMR) spectroscopy, and checked peak purity with diode-array ultraviolet and LC-MS detection.
[Figure 2. How an impurity profile is tracked. A 2007 case series set the method for MK-0677 as a raw ingredient: screening columns and mobile-phase pH, separating related substances, identifying them by mass spectrometry and NMR, then checking each peak’s purity.]
What a chromatogram of that kind can and cannot resolve sets the limits of HPLC in SARMs testing. Analysis of this sort establishes what a lot contains, which is why batch and purity data accompany the MK-677 for sale here for laboratory research, as they accompany the rest of the UK SARMs range.
What could there be inside fake mk677?
Inside fake MK677 there could be something other than what its label states. Appearance, colour, taste and packaging are widely understood to reveal nothing reliable about MK-677 quality, so only an analysis by mass spectrometry or HPLC settles what a preparation contains and in what amount, and laboratory analyses of products sold as research compounds commonly find the following:
Less of the declared compound than stated
More of the declared compound than stated
No active compound at all
Another substance in place of the declared compound, usually another selective androgen receptor modulator, the peroxisome proliferator-activated receptor-delta agonist GW501516 or the Rev-ErbA agonist SR9009
Fillers and residues left from manufacture
Oral and injected ibutamoren in the animal studies
Data on ibutamoren injection come from animals alone, from a balanced crossover study in eight beagles. Oral doses of 0.25, 0.50 and 1.0 mg/kg raised peak growth hormone in those dogs by progressively larger multiples, as the chart below shows, and an intravenous dose of 0.25 mg/kg raised it by more than any of the oral doses did, to 77.4 ng/ml, with the maximum reached at 10 minutes and concentrations still elevated at 180 minutes.
The oral route gave the longer growth hormone response in the same animals: after 1 mg/kg the peak came at 120 minutes, and growth hormone stayed raised for up to 360 minutes. Both routes raised IGF-1, by 30 per cent after oral and by 25 per cent after intravenous dosing, cortisol rose about 2.3- to 2.4-fold by either route, and lower oral doses still, down to 0.125 mg/kg, were enough to raise growth hormone in dogs.
Rodent work qualifies that picture: in rats an oral 4 mg/kg dose raised peak growth hormone 1.8-fold, but after six weeks of dosing the response was abolished, and neither body growth nor IGF-1 increased. The intravenous dose given to beagles stands as a pharmacological experiment rather than as evidence about a solution formulated for oral dosing.
[Figure 3. Oral versus intravenous ibutamoren in beagles. In a balanced crossover of eight beagles, single oral doses of 0.25, 0.50 and 1.0 mg/kg raised peak growth hormone 5.3-, 9.0- and 15.8-fold, while 0.25 mg/kg intravenously raised it 20.4-fold.]
What the evidence on MK-677 forms leaves open
The evidence on MK677 liquid, capsules and the other forms leaves the dosage form itself unrecorded, because the trial literature settles only the route: the two-year trial states an oral dose of 25 mg once daily and, like the shorter trials, names no tablet, capsule or solution. Injected dosing is documented only in beagles, in which an intravenous dose was compared with oral doses, and the one body of stability data concerns compounds in serum, plasma and dried blood spots held at defined temperatures, not a bottled preparation standing in a solvent. No published study among this article’s sources has compared one dosage form of ibutamoren with another in humans, and none has measured the matters known only from descriptions outside the trials:
Taste
Smell
Colour
Crystals and sediment
Foaming
The choice of solvent
Capsule filling
Behaviour in heat
Shelf life
Refrigeration
The digestive complaints attributed to carriers
The FDA’s compounding listing of ibutamoren mesylate concerns the material pharmacies may use and rests on MK677 heart problems; it says nothing of liquid against capsules or powder.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What do the human trials of ibutamoren record about the form it was given in?
The oral route, but not tablet, capsule or solution ✓
Capsules in every trial, from children to older adults
A ready-made solution in most of the adult trials
Tablets for adults and a liquid for the children
The trials, including the two-year one, state that ibutamoren was given orally once a day, but none says whether it was a tablet, a capsule or a solution.
In the beagle study, how did oral ibutamoren compare with intravenous ibutamoren?
Intravenous gave the higher peak, oral the longer response ✓
Oral gave the higher peak, intravenous the longer one
Both routes gave nearly the same peak and the same duration
Intravenous raised IGF-1 while oral left it unchanged
In eight beagles, intravenous ibutamoren lifted peak growth hormone about 20-fold within 10 minutes, while the oral route kept it raised for up to 360 minutes. These dogs are the only source of data on injected ibutamoren.
What can the colour of ibutamoren powder or solution tell about a batch?
Little, since the normal and suspect colour ranges overlap ✓
A beige or yellow tint shows that the compound has broken down
Pure white is a reliable sign of an authentic batch
A darker shade shows how long it has been stored
The colours described as normal overlap those described as suspect, so only an analysis such as HPLC impurity profiling can tell batches apart.
Where do this article's laboratory stability data for ibutamoren come from?
Blood specimens tested in a doping-control method paper ✓
A shelf-life study of bottled ibutamoren solutions
A storage trial of finished capsules kept at room temperature
A heat test of powder held in parcels during transit
The only stability figures concern serum, plasma and dried blood spots held at set temperatures. Ibutamoren was not among the compounds that broke down, and no bottled preparation was studied.
Research Fellow in Digital Drug Product Development
Bilal Ahmed is a research fellow in digital drug product development at CMAC, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde. Bilal specialises in formulation science.
Lecturer in Analytical Chemistry; Biochemistry course leader
Alexandra Males is a lecturer in analytical chemistry and the biochemistry course leader at Sheffield Hallam University. Alexandra specialises in analytical chemistry, HPLC and chromatography, mass spectrometry, reference standards and metrology, and stability and impurity profiling.
Legit RAD 140 is shown only by a lab test of the bottle’s batch, as analyses found products missing the compound, under-strength or with other hormones.
RAD 140 liquid holds the same compound as capsules, powder and injectables, dissolved in a carrier, so it differs in how it is measured and how it keeps.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
MK677 liquid: capsules, powder, injectables and storage
By Bilal Ahmed, PhD · Reviewed by Alexandra Males, PhD
Published · Updated · 22 min read
How MK677 liquid compares with capsules, powder and injections
MK677 liquid, capsules, tablets and powder all hold the same compound, ibutamoren, and the human trials gave it orally because it was designed as an orally active releaser of growth hormone, the pituitary hormone that drives growth and tissue repair; that role as a releaser is what separates MK-677 and HGH. The liquid is the powder dissolved in a solvent.
Outside the published trials, that solvent is described as the cause of the harsh taste of the bottled forms, and their storage is described only in such accounts, never in a stability study of a finished product.
What is MK 677, the compound behind all of these forms? Ibutamoren, a small molecule (not a peptide) selected for clinical study because it raised growth hormone after oral dosing; the human trials gave it orally once daily, and no human data stand behind an injectable form, since intravenous administration, delivery of a dose directly into the bloodstream, is documented only in beagles. What separates the bottled forms is the solvent and the handling, not the molecule.
This article compares the dosage forms of ibutamoren through what the trials, the animal studies and the accounts outside them say about each form and its storage; the physiological and adverse effects of the compound stay outside it, and so does dose except where it bears on a form.
Oral ibutamoren in the human trials
Every human trial among this article’s sources gave ibutamoren orally, once daily. In the longest, healthy older adults received the daily oral dose set out in the table, and growth hormone rose into the range of healthy young adults, as did insulin-like growth factor 1 (IGF-1), the growth factor that mediates growth hormone’s effects on tissues; the same daily dose went to obese men over a shorter course and raised IGF-1 in their serum.
The shorter trials kept to the same route. A crossover trial gave that daily dose to healthy volunteers held on a restricted diet; prepubertal children with growth hormone deficiency received the compound as ibutamoren mesylate (the salt used in the clinical programme) at the two body-weight doses the table records; and in haemodialysis patients on the same route the rise in IGF-1 was greater than on placebo.
Oral ibutamoren across the human trials
The records state the route and the dose, and none says whether a daily dose was given as a tablet, a capsule or a solution: the dosage form was never the variable under study, so the trial literature settles the route and leaves the form open.
Why growth hormone is injected while ibutamoren is swallowed
Growth hormone itself has to be given subcutaneously, by injection into the tissue beneath the skin, whereas ibutamoren was designed to act after oral administration. The difference is one of oral bioavailability, the fraction of an administered dose that reaches the circulation intact, the measure that also sets SARM bioavailability after oral administration.
Ibutamoren acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor, in the hypothalamus and in the pituitary, a receptor distinct from the one for growth hormone-releasing hormone, so the two pathways are separate; through it, in the hypothalamus and then the pituitary, the growth hormone secretagogue MK 677 raises growth hormone.
The same receptor is the target of the growth hormone-releasing peptides, short synthetic growth-hormone secretagogues that raise growth hormone after intravenous, subcutaneous, intranasal and even oral administration, and a review of the class names MK-0677 as the most interesting of their non-peptidyl mimics. That interest rested on earlier animal work, ibutamoren having been selected for clinical study after oral doses raised growth hormone in dogs, which places the oral route at the origin of the molecule rather than at the end of its development.
Ibutamoren capsules in a hair-testing study
Ibutamoren capsules enter the published record outside the trials through a hair-testing study that established reference concentrations by hair analysis, the measurement of a compound incorporated into the hair shaft. A male volunteer received a single dose, and a drug test for MK 677 on hair collected weeks later came back positive, at the concentration given in the table in picograms of compound per milligram of hair, in the segment nearest the scalp.
The second specimen came from a subject whose exposure amounted to a whole vial of capsules, and hair collected after that exposure ended tested positive at the far higher concentration the table records; the capsules also document a stated unit strength, recorded in the table, a point beyond the detection question the paper was written to answer.
Two hair specimens after ibutamoren capsules
Which is best, pill form or liquid form?
Pill and liquid are described, outside the trial record, as carrying the same molecule and differing in handling rather than in the compound, which is the usual verdict on liquid SARMs vs pills as well: a pill, whether an MK-677 tablet or a capsule, holds a fixed amount in each unit, so a stated strength needs no measuring and the taste of the material stays enclosed, while MK 677 drops allow the amount drawn to be varied by volume.
In descriptions beyond the trials, MK677 in liquid form, made up as a solution from powder, is widely described as costing less per gram than finished units, and the saving comes with the taste of the solution, with a container that has to be kept sealed and dark, and with a strength that cannot be confirmed by eye.
Why does MK-677 liquid taste so bad, and how can you mask it?
The taste of MK-677 liquid is the effect raised most often among those described outside the trials, and its cause is attributed in two ways, to the solvent that carries the compound and to the raw material itself: the taste is strongly bitter and chemical, in some accounts with a note of alcohol behind it, and accounts that set out what MK 677 does taste like call it worse than other research compounds prepared as solutions, ostarine liquid and solutions of several related materials being faintly sweet or almost without flavour where the ibutamoren solution is difficult to tolerate.
In descriptions beyond the trials a minority of accounts run the other way, the powder off-white with no smell and no flavour at all and the solution tasting of almost nothing, an absence of the expected bitterness that is then read as grounds for doubting that a bottle holds what the label states, and so for seeking an analysis of the batch. Attempts to mask the bad taste of MK-677 are described too, and most are said to fail or to spread the taste rather than hide it:
Should MK-677 liquid have a smell?
Beyond the trial data the smell of MK-677 liquid is described inconsistently, so whether the bottled solution should have any is not agreed: some accounts have no scent at all from either the powder or the solution, set beside a markedly bitter taste, others a distinct and unpleasant odour as the usual character of the material, so that its absence is treated as odd, and an absence of both smell and taste, in a solution or in capsules, is sometimes read as a reason to doubt what the preparation contains.
Can you mix MK-677 with water or a drink to take it?
Mixing MK-677 with water or with a drink has also been described as straightforward, because the compound is readily soluble: the powder dissolves at room temperature with little difficulty in distilled and demineralised grades and in deionised water (stripped of its dissolved ions), a measured volume of an existing solution goes into a glass of juice or a carbonated drink, and a clear solution stays so when diluted that way.
Not every account outside the published studies agrees, and a minority of those accounts describe the compound as not dissolving properly in water and as needing another carrier, leaving unsettled whether water given soon after oral administration of the compound makes any difference; the contrast with other research compounds is drawn repeatedly, since the solubility of LGD-4033 and of similar compounds is nil in water, so that they require a glycol, and the question of whether a capsule can be emptied and its contents dissolved is raised, as is the reverse, a solution loaded into capsules.
How do you dissolve MK-677 powder into a liquid, and which solvent works?
Accounts outside the published studies describe ibutamoren powder as dissolving in several carriers, with no single one treated as correct: distilled and deionised water, propylene glycol (a viscous dihydric alcohol used as a pharmaceutical carrier), polyethylene glycol (PEG), a water-soluble polymer supplied in grades of average molecular weight such as the liquid PEG-400, ethanol, and dimethyl sulfoxide (DMSO), a polar solvent that dissolves many organic compounds. MK 677 solubility is described differently from one account to another, some treating water as sufficient on its own, others naming glycol and glycol-with-DMSO mixtures where a small volume has to hold a higher concentration.
Beyond the trial data, the method of preparation is volumetric rather than approximate: the raw MK 677 powder is weighed on a milligram balance, dissolved in part of the final volume and then made up to that volume, because the dissolved material occupies space of its own and a volume of solvent measured alone gives an incorrect concentration; small quantities are impossible to judge by eye, and an inexpensive balance is named as the limiting step.
Does MK-677 solution contain ethanol, and what solvent is used?
An MK-677 solution is made, in descriptions beyond the trials, with ethanol in some cases, with water in others and with a mixture of the two and a glycol in others again, preparations built on near-pure grain ethanol standing alongside water-only ones; labels that state no composition prompt the question of whether a given bottle contains ethanol, and the taste of such solutions is attributed most often to the solvent rather than to the compound itself.
Digestive complaints blamed on the solvent
Beyond the trial data, a small set of gastrointestinal effects is described and attributed to the carrier rather than to the compound: gastric upset, rarely, in connection with a suspension, a preparation in which solid material is dispersed rather than dissolved, attributed to the solvent of that particular batch, and the same carrier singled out once as tasting unlike the other solutions of the same range and as marking the graduations on a glass dropper.
What colour should MK-677 be, and is beige or yellow normal?
In descriptions beyond the trials, the colour of MK-677 powder and of its solutions spans a described range, so beige and yellow both fall inside it, and batches differ from one another:
Beyond the trial data, ibutamoreno powder is white before dissolution, and other appearances are grounds for concern: powder that changed colour in storage is taken to have broken down, or never to have been the stated compound. Reassuring and suspicious accounts alike reach one conclusion by different routes, that colour alone cannot tell a sound batch from a suspect one, because the range held to be normal overlaps the range held to be suspect, and only an analysis tells the two apart.
Are white bits or crystals floating in MK-677 liquid normal?
Among the effects described outside the trials, white bits and crystals in MK-677 liquid are common enough to take several recognised forms:
Those deposits are given two explanations outside the trial record: material that never dissolved fully settles out, and water taken up from the air forms a hydrate crystal, a solid in which water molecules sit within the crystal lattice; a solution left in the cold is also described as setting almost solid and then, as it warms, returning to a clear liquid.
Why does MK-677 liquid foam or bubble when shaken?
MK-677 liquid is generally held to foam on shaking because of its carrier rather than because of any change in the compound: the viscous solvents propylene glycol and polyethylene glycol trap air readily and release it slowly, as do preparations containing ethanol, so bubbles of this kind settle out on standing, while persistent foam points to a surface-active component in the preparation, one that cannot be identified from appearance alone.
How do you make your own MK-677 capsules?
MK-677 capsules are described, outside the trial record, as made by weighing the powder on a milligram balance and filling it into empty gelatin capsules, two-piece shells of gelatin that separate for filling, the usual alternative both to the taste of the bottled solution and to the price of finished units; the limiting step is the balance, not the shell.
In descriptions beyond the trials, several questions recur around that weighing step. The capacity of a given shell size is put in terms of displacement (the volume a weighed solid occupies in the capsule body), because a shell holds a volume and not a mass; the transfer of an existing solution into gelatin shells raises the open question of whether the transfer alters the compound; attempts to split a quantity between filled capsules and a solution are described; and one account adds a precaution, that a shell filled this way should contain the single compound and no other substance.
What laboratory stability data show for ibutamoren
The nearest thing to stability data among this article’s sources is a doping-control method paper on blood matrices, whose conditions the table below sets out. Several peptide doping agents were extensively degraded in serum and in plasma under the warmer of the conditions tested, and ibutamorenum was not among the compounds that broke down; in the freezer every analyte in the panel remained stable, within the variation and over the period the table records, in all the blood matrices examined.
Stability by temperature and blood matrix
Dried blood spots, drops of whole blood dried onto a paper card, kept all of the compounds detectable for the whole study too, so such specimens can be transported and held without refrigeration. The figures describe analytical specimens rather than a product standing in a solvent, and they carry no further; heat, light and moisture each act on research compounds in a distinct way, so storing SARMs safely depends on guarding against each of the three separately.
Is MK-677 still good after being exposed to high heat?
MK-677 is described, outside the trial record, as tolerating extremes of temperature better than peptides do, and a solution carried through transit at uncontrolled temperatures as having lost little in a few accounts; high heat is the extreme raised most often, cold is raised in the same terms, and several accounts record no confidence either way without an analysis of the batch in hand. The exposures described are these:
Is an old bottle of MK-677 still good after one or two years?
An old bottle of MK-677 has also been described as having lost little when its solution was analysed long after preparation, though only in a few accounts; in others colour and clarity are the only checks short of an analysis. Stability of that kind is judged in terms of shelf life, the period over which a preparation is held to remain within its stated strength, and the bottles in question include sealed and unopened ones recovered years later and a half-used one kept in a cupboard; the MK677 shelf life after opening is treated as a separate question, because some labels state a period measured in months.
Should MK-677 liquid go in the fridge or freezer, or a cupboard?
MK-677 liquid and capsules alike are described, in accounts outside the published studies, as keeping well enough in a cool, dry, dark cupboard, the absence of any need for refrigeration counting as an advantage over materials that must be refrigerated; refrigeration is also said to turn a solution semi-solid until it warms again, the freezer is named for storage over long periods, and the powder itself is hygroscopic, readily taking up water from the air, so sealed storage is described for it and powder that has hardened is taken to have absorbed moisture.
How ibutamoren batches are checked for purity
Chromatography is how ibutamoren batches are checked for purity, and one analytical case series sets out such a method for MK-0677 as an active pharmaceutical ingredient, the compound itself as distinct from a finished preparation. The series used reversed-phase high-performance liquid chromatography (HPLC), which separates compounds on a column before they reach the detector, to track the impurity profile, the identity and amount of the related substances present; the authors arrived at the method by screening stationary phases and varying the pH of the mobile phase, identified individual impurities by liquid chromatography-mass spectrometry (LC-MS), preparative chromatography and nuclear magnetic resonance (NMR) spectroscopy, and checked peak purity with diode-array ultraviolet and LC-MS detection.
What a chromatogram of that kind can and cannot resolve sets the limits of HPLC in SARMs testing. Analysis of this sort establishes what a lot contains, which is why batch and purity data accompany the MK-677 for sale here for laboratory research, as they accompany the rest of the UK SARMs range.
What could there be inside fake mk677?
Inside fake MK677 there could be something other than what its label states. Appearance, colour, taste and packaging are widely understood to reveal nothing reliable about MK-677 quality, so only an analysis by mass spectrometry or HPLC settles what a preparation contains and in what amount, and laboratory analyses of products sold as research compounds commonly find the following:
Oral and injected ibutamoren in the animal studies
Data on ibutamoren injection come from animals alone, from a balanced crossover study in eight beagles. Oral doses of 0.25, 0.50 and 1.0 mg/kg raised peak growth hormone in those dogs by progressively larger multiples, as the chart below shows, and an intravenous dose of 0.25 mg/kg raised it by more than any of the oral doses did, to 77.4 ng/ml, with the maximum reached at 10 minutes and concentrations still elevated at 180 minutes.
The oral route gave the longer growth hormone response in the same animals: after 1 mg/kg the peak came at 120 minutes, and growth hormone stayed raised for up to 360 minutes. Both routes raised IGF-1, by 30 per cent after oral and by 25 per cent after intravenous dosing, cortisol rose about 2.3- to 2.4-fold by either route, and lower oral doses still, down to 0.125 mg/kg, were enough to raise growth hormone in dogs.
Rodent work qualifies that picture: in rats an oral 4 mg/kg dose raised peak growth hormone 1.8-fold, but after six weeks of dosing the response was abolished, and neither body growth nor IGF-1 increased. The intravenous dose given to beagles stands as a pharmacological experiment rather than as evidence about a solution formulated for oral dosing.
What the evidence on MK-677 forms leaves open
The evidence on MK677 liquid, capsules and the other forms leaves the dosage form itself unrecorded, because the trial literature settles only the route: the two-year trial states an oral dose of 25 mg once daily and, like the shorter trials, names no tablet, capsule or solution. Injected dosing is documented only in beagles, in which an intravenous dose was compared with oral doses, and the one body of stability data concerns compounds in serum, plasma and dried blood spots held at defined temperatures, not a bottled preparation standing in a solvent. No published study among this article’s sources has compared one dosage form of ibutamoren with another in humans, and none has measured the matters known only from descriptions outside the trials:
The FDA’s compounding listing of ibutamoren mesylate concerns the material pharmacies may use and rests on MK677 heart problems; it says nothing of liquid against capsules or powder.
Check what you remember
4 questions on this article; the right answer is marked.
The trials, including the two-year one, state that ibutamoren was given orally once a day, but none says whether it was a tablet, a capsule or a solution.
In eight beagles, intravenous ibutamoren lifted peak growth hormone about 20-fold within 10 minutes, while the oral route kept it raised for up to 360 minutes. These dogs are the only source of data on injected ibutamoren.
The colours described as normal overlap those described as suspect, so only an analysis such as HPLC impurity profiling can tell batches apart.
The only stability figures concern serum, plasma and dried blood spots held at set temperatures. Ibutamoren was not among the compounds that broke down, and no bottled preparation was studied.
Bilal Ahmed, PhD · University of Strathclyde
Research Fellow in Digital Drug Product Development
Bilal Ahmed is a research fellow in digital drug product development at CMAC, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde. Bilal specialises in formulation science.
Alexandra Males, PhD · Sheffield Hallam University · Last reviewed
Lecturer in Analytical Chemistry; Biochemistry course leader
Alexandra Males is a lecturer in analytical chemistry and the biochemistry course leader at Sheffield Hallam University. Alexandra specialises in analytical chemistry, HPLC and chromatography, mass spectrometry, reference standards and metrology, and stability and impurity profiling.
Related Posts
Legit RAD 140: fakes, under-strength products and lab tests
Legit RAD 140 is shown only by a lab test of the bottle’s batch, as analyses found products missing the compound, under-strength or with other hormones.
RAD 140 liquid: capsules, powder and injectables compared
RAD 140 liquid holds the same compound as capsules, powder and injectables, dissolved in a carrier, so it differs in how it is measured and how it keeps.